From the Editor

In the news, now on the shelf: A novel estradiol-based OC

Author and Disclosure Information

 

References

Natazia for menorrhagia

As I noted, Natazia appears to be associated with 1) fewer days of menstrual bleeding and 2) more cycles without withdrawal bleeding than an EE-LNG contraceptive.5 These findings suggest that Natazia may be especially useful for treating heavy menstrual bleeding.

Two randomized clinical trials that were reported in abstracts at major professional meetings have tested this hypothesis6,7:

Trial #1. 190 women who had heavy menstrual bleeding were randomized to Natazia or placebo6:

  • 44% of women who took Natazia experienced complete improvement in their heavy menstrual bleeding
  • Only 4% of women in the placebo group experienced such improvement
  • Natazia, but not placebo, was associated with an elevation in hematocrit, hemoglobin concentration, and ferritin level.

Trial #2. In a trial conducted to likewise test the efficacy of Natazia for heavy menstrual bleeding, the rate of complete improvement among women treated with Natazia was 41%; the rate was 2% in the placebo group.7

These studies show that Natazia may be especially useful for women who report heavy menses when they’ve taken other estrogen-progestin contraceptives.

More choices mean better tailoring

Effective counseling and consistent use of a contraceptive will reduce the high rate of unintended pregnancy in the United States. Having many contraceptive options available helps ensure that each woman can find the contraceptive that’s best suited to her.

We want to hear from you! Tell us what you think.

What do you know about the enzyme CYP3A4 and how it affects the work of some OCs? Take the Instant Quiz.

Next Article: